ABSTRACT
Bites of Bitis Rhinoceros (Viperidae) usually cause a hemorrhagic syndrome in the victims. This is a medical emergency. Antivenom immunotherapy remains effective. However, its availability and cost still limiting its use in Africa in general and in Côte d'Ivoire particularly. The roots of a plant of the Annonaceae family (Annona senegalensis) are used in Côte d'Ivoire to treat cases of envenomations by Viperidae. The objective of this work is to study the modulation of the effect of Bitis rhinoceros venom on coagulation parameters by the hydroethanol extract of Annona senegalensis leaves. The phytochemical study of the plant was carried out by monitoring effect of the venom on three blood coagulation parameters (PT, APTT, Fibrinogen) from healthy individuals in the presence and absence of the hydro-ethanolic extract. Phytochemistry revealed the presence of saponins, tannins, and polyphenolic compounds including flavonoids in this plant. The study of the effect of the venom showed that at the concentration of 10-2 mg/mL the venom of Bitis rhinoceros modifies some coagulation parameters by the decrease of half of the prothrombin rate, the increase of the coagulation time. It has no effect on the fibrinogen level. The effect of this venom is inhibited by 1 mg/mL of the hydroethanol extract. The leaves of Annona senegalensis contain molecules that could neutralize the action of the venom in the coagulation disorder.
ABSTRACT
Introdução: A reestenose intrastent (RIS), resultante da excessiva resposta reparadora neointimal após o implante da prótese, é uma das principais limitações da intervenção coronária percutânea. A despeito da eficácia dos stents farmacológicos (SF) de primeira geração no tratamento da RIS, questões relacionadas à segurança e ao perfil de flexibilidade/navegabilidade dessas próteses estimularam o desenvolvimento de novas gerações de SF. O novo SF Firebird TM (Microport Co. Ltd., Xangai, China) combina uma plataforma de aço inoxidável (316 L) de hastes finas (0,0040 polegada), um potente agente antiproliferativo (sirolimus, na dose de 9 ug/mm2) e um revestimento que inclui três camadas de polímero durável, que controla a liberação do fármaco. Apesar de ser um dos SF mais utilizados na China, pouco se conhece sobre seu desempenho, sobretudo em subgrupos de maior complexidade. Método: Entre fevereiro e dezembro de 2009, pacientes portadores de lesão reestenótica única, de stents não-farmacológicos, foram submetidos a intervenão coronária percutânea com implante de stent Firebird TM. Avaliação com angiografia ultrassom intracoronário (USIC) foi programada para todos os pacientes...
BACKGROUND: In-stent restenosis (ISR), resulting from excessive neointimal hyperplasia, is a major limitation of percutaneous coronary intervention. Despite the efficacy of first generation drug-eluting stents (DES) in the treatment of ISR, issues related to the safety and flexibility/navigability profile have encouraged the development of new generations of DES. The new FirebirdTM DES (Microport Co. Ltd., Shanghai, China) combines a stainless steel platform (L316) of fine struts (0,0040'), a powerful anti-proliferative agent (sirolimus, at a dose of 9 µg/mm²) and a coating that includes three layers of a durable polymer, which controls drug release. Though it is a most used DES in China, little is known about its performance, particularly in subgroups of greater complexity. METHOD: Between February and December 2009, patients with single bare metal stent restenotic lesions, were submitted to percutaneous coronary intervention with FirebirdTM stent implantation. Angiography and intravascular ultrasound (IVUS) were scheduled for all patients at 12 months of follow-up. The primary end-point was late loss and the percentage of in-stent volumetric obstruction at 12 months. RESULTS: Twenty-five patients with mean age of 56.8 ± 7.7 years were included, of which 80% were males and 40% diabetics. The anterior descending artery was the most frequently treated vessel (44%) and most lesions had a diffuse/proliferative pattern (64%). At 12 months, late luminal loss was 0.3 ± 0.24 mm, and no case of binary restenosis was identified. IVUS percent volumetric obstruction was 2.6 ± 1.9%. CONCLUSION: In this single center study, the new FirebirdTM DES showed favorable angiographic and IVUS results for the treatment of bare metal ISR at the one year follow-up.